Janssen

Janssen’s Nucynta meets primary endpoint in diabetic peripheral neuropathy study

Monday, May 21, 2012 02:46 PM

Janssen Pharmaceuticals has issued results from an investigational phase III study suggesting Nucynta ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy (DPN).

More... »

Index Ventures launches $198 million life sciences fund

Wednesday, March 21, 2012 09:26 AM

Index Ventures, a venture capital firm, has launched its first fund solely dedicated to making investments in the life sciences sector.

More... »

Academic-industry collaboration seeks new drugs, treatments for autism

Monday, March 19, 2012 02:41 PM

An international consortium of scientists led by Roche, King's College London and Autism Speaks is collaborating on one of the largest ever academic-industry research projects, to find new methods for the development of drugs for autism spectrum disorder (ASD), which affects 1% of children worldwide.

More... »

Selventa and Janssen form research agreement

Monday, February 27, 2012 03:15 PM

Cambridge, Mass.-based Selventa, a personalized healthcare company focused on development of predictive biomarker panels, has formed a multi-year research agreement with Janssen R&D in immunological disease.

More... »

J&J’s Alex Gorsky succeeds Bill Weldon as CEO

Saturday, February 25, 2012 06:34 AM

Johnson & Johnson’s board of directors has named Alex Gorsky CEO of J&J effective April 26, 2012, the date of the company’s annual meeting of shareholders.  

More... »

Pepscan achieves milestones from Janssen

Saturday, February 11, 2012 07:53 AM

Pepscan Therapeutics, a Netherlands-based biotechnology firm focusing on protein mimicry technology, has achieved two milestones in the research collaboration with Janssen R&D Ireland, formerly Tibotec Pharmaceuticals, and received undisclosed payments. 

More... »

NICE refuses to recommend Janssen’s Zytiga for prostate cancer

Wednesday, February 8, 2012 09:58 AM

The National Institute for Health and Clinical Excellence (NICE), the U.K. healthcare guidance body, has issued new draft guidance not recommending the use of Zytiga (abiraterone), developed by Janssen, in combination with prednisone or prednisolone for the treatment of castration-resistant metastatic prostate cancer that has progressed on or after docetaxel-containing therapy.

More... »

Alzheimer's Challenge 2012 seeks new tools to improve Alzheimer's care

Thursday, January 26, 2012 10:47 AM

South San Francisco-based Janssen Alzheimer Immunotherapy, together with Pfizer—its collaborator on the Alzheimer's Immunotherapy Program (AIP)—and the Geoffrey Beene Gives Back Alzheimer's Initiative, have introduced the Alzheimer's Challenge 2012, calling for inventive concepts to help improve the diagnostic identification and tracking of Alzheimer's disease.

More... »

Forma and Janssen to collaborate on cancer drug

Wednesday, January 11, 2012 11:19 AM

Forma Therapeutics has formed an exclusive alliance with Janssen Biotech (a subsidiary of Johnson & Johnson), in which the pair will collaborate on discovery, development and commercialization of novel small molecule drug candidates that target tumor metabolism mechanisms.

More... »

Metamark, Janssen ink $365 million research agreement

Tuesday, December 20, 2011 01:12 PM

Metamark Genetics has entered into a research, collaboration, and license agreement with Janssen Biotech. The agreement is based on Metamark's discovery platform for the identification and characterization of specific proprietary cancer targets demonstrated to play a causal role in promoting tumor progression and spread. The collaboration will focus on the evaluation and validation of several of Metamark's Prognosis Determinants. Upon selection of the targets, Janssen Biotech will receive a limited exclusive license under Metamark's intellectual property and know-how and will thereafter be responsible for the discovery, development, and commercialization of therapeutic inhibitors targeting the specific Prognosis Determinants.

More... »